1st Quarter - Report

MUSCULAR DYSTROPHY ASSOCIATION, INC. for MUSCULAR DYSTROPHY ASSOCIATION, INC.

Firm
Client
Income
—
Expenses
$100,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

9 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Health care issues affecting individuals with neuromuscular disease including therapy development, newborn screening, screening and diagnosis, adequate insurance coverage, and access to care. Advocated for the passage of the Newborn Screening Saves Lives Reauthorization Act, H.R. 482 / S. 350, to encourage investment in the national newborn screening program in order to detect more neuromuscular conditions early to speed appropriate interventions for patients. Advocated for robust funding of the national newborn screening program. Advocated for increased funding for National Institutes of Health, Food and Drug Administration, Health Resources and Services Administration, Centers for Disease Control and Prevention, and other health agencies that conduct research on neuromuscular disease and provide services to those with these conditions. Advocated for adequate, affordable, accessible health coverage for individuals with neuromuscular conditions. Advocated for the swift funding and implementation of the ACT for ALS Act (S.1813 and H.R.3537). Advocated for access to healthcare via telemedicine/telehealth throughout and after the COVID-19 public health emergency. Advocated for the passage of the Air Carrier Access Amendments Act (S.642 and H.R.1696) Advocated for closure of the Medicaid coverage gap and the permanence of the Advanced Premium Tax Credits as part of the Build Back Better Act. Advocated for a robust paid medical leave program. Advocated for the Transformation to Competitive Integrated Employment Act (H.R.2373 and S.3238) Advocated for increased funding of home and community-based services (HCBS). Advocated for passage of the Disability Employment Incentive Act. Supported the passage of the e Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act (H.R. 5030/S. 2706) Advocated for the permanent adoption of the changes to the Earned Income Tax Credit (EITC) and the Child Tax Credit (CTC). Provided feedback and comments to the Senate's PREVENT Act.

LobbyistCovered position, as disclosed
MICHAEL KENNALLY LEWIS New —
PAUL MELMEYER —

Contacted: SENATE; Natl Council on Disability; Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Labor, Dept of (DOL); Natl Institutes of Health (NIH); Centers For Medicare and Medicaid Services (CMS); Natl Institute of Standards & Technology (NIST); Health Resources & Services Administration (HRSA); Treasury, Dept of; Health & Human Services, Dept of (HHS)

Bills named: S. 1813 (117th), H.R. 1696 (117th), H.R. 2373 (117th), S. 350 (117th), H.R. 3537 (117th), S. 642 (117th), S. 2706 (117th), H.R. 482 (117th), H.R. 5030 (117th), S. 3238 (117th)

Aviation/Airlines/Airports AVI

Advocated for the passage of the Air Carrier Access Amendments Act (S.642, H.R.1893) Advocated for further air travel access improvements for individuals with disabilities through regulation by FAA and DoT.

LobbyistCovered position, as disclosed
MICHAEL KENNALLY LEWIS —
PAUL MELMEYER —

Contacted: HOUSE OF REPRESENTATIVES; Federal Aviation Administration (FAA); Transportation, Dept of (DOT); SENATE

Bills named: S. 642 (117th), H.R. 1893 (117th)

Budget/Appropriations BUD

Advocated for robust funding for the Newborn Screening programs at the CDC, NIH, and HRSA Advocated for robust funding for the NIH and FDA through increased appropriations. Advocated for increased funding of the National Center for Advancing Translational Sciences (NCATS)

LobbyistCovered position, as disclosed
MICHAEL KENNALLY LEWIS —
PAUL MELMEYER —

Contacted: HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); SENATE

Medical/Disease Research/Clinical Labs MED

Advocated in favor of robust appropriations funding for the National Institutes of Health, the Food and Drug Administration, the Health Resources and Services Administration, and the Centers for Disease Control and Prevention. Advocated for greater appropriations for the National Center for Advancing Translational Sciences (NCATS) Advocated for greater appropriations for the National Institutes of Health. Advocated for appropriations for HHS, NIH, and FDA to implement the ACT for ALS. Provided feedback and comments to the Senate's PREVENT Act.

LobbyistCovered position, as disclosed
PAUL MELMEYER —

Contacted: Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Medicare/Medicaid MMM

Advocated for adequate, affordable, accessible health coverage for individuals with neuromuscular conditions. Supported additional coverage expansions by advocating that certain policies, such as permanent advanced premium tax credits and the closing of the Medicaid gap, are added to the Build Back Better Act. Supported substantially increased funding to HCBS 1915 waivers. Advocated for the passage of the STOP the WAIT Act (H.R.4386 and S.2496).

LobbyistCovered position, as disclosed
MICHAEL KENNALLY LEWIS —
PAUL MELMEYER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 4386 (117th), S. 2496 (117th)

Insurance INS

Advocated for adequate, affordable, accessible health coverage for individuals with neuromuscular conditions. Advocated for permanent continuance of the advanced premium tax credits. Advocated for access to healthcare via telemedicine/telehealth throughout and after the COVID-19 public health emergency.

LobbyistCovered position, as disclosed
MICHAEL KENNALLY LEWIS —
PAUL MELMEYER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Labor Issues/Antitrust/Workplace LBR

Advocated for specific regulatory and administrative approaches to implementing the No Surprises Act. Advocated for the Transformation to Competitive Integrated Employment Act (H.R.2373 and S.3238) Advocated for the passage of the Disability Employment Incentive Act. Advocated for a robust paid medical leave program.

LobbyistCovered position, as disclosed
MICHAEL KENNALLY LEWIS —
PAUL MELMEYER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Treasury, Dept of; Labor, Dept of (DOL); Health & Human Services, Dept of (HHS)

Bills named: S. 3238 (117th), H.R. 2373 (117th)

Pharmacy PHA

Advocated for funding and implementation of the ACT for ALS, a law that should accelerate development of treatments for individuals with ALS and other neuromuscular diseases. Advocated for the passage of the Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act (H.R. 5030/S. 2706) Provided feedback and comments to the Senate's PREVENT Act.

LobbyistCovered position, as disclosed
PAUL MELMEYER —

Contacted: SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Bills named: S. 2706 (117th), H.R. 5030 (117th)

Taxation/Internal Revenue Code TAX

Advocated for permanency of the Advanced Premium Tax Credit for accessing quality, affordable health insurance. Supported the Disability Employment Incentive Act, legislation that doubles incentives for businesses to hire individuals with disabilities. Supported the enactment of the SSI Restoration Act. Advocated for the permanent adoption of the changes to the Earned Income Tax Credit (EITC) and the Child Tax Credit (CTC).

LobbyistCovered position, as disclosed
MICHAEL KENNALLY LEWIS —
PAUL MELMEYER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.